Document:

<PAGE>

                                                                   EXHIBIT 10.46

                            STOCK PURCHASE AGREEMENT

                  This agreement is dated December 10, 2001 between ____________
("Purchaser"), and NeoTherapeutics, Inc. ("Company"), whereby the parties agree
as follows:

         The Purchaser shall buy and the Company agrees to sell _______ shares
("Shares") of the Company's Common Stock at a price of $3.85 per share for a
total amount of $___________. The Shares have been registered on a Form S-3,
File No. 333-53108, which registration statement has been declared effective by
the Securities and Exchange Commission. The Shares are free of restrictive
legends and are free of any resale restrictions. The Company is delivering
herewith a prospectus supplement on Form 424 (b)(2) regarding the sale of the
Shares prior to funding.

         The Purchaser shall wire the purchase amount to the Company to the
account set forth below.

Company Wire Transfer Instructions:

         Chase Manhattan Bank
         1 Chase Plaza
         New York, NY 10004
         ABA # 021 000 021
         FBO Salomon Smith Barney
         A/C # 066-198038
         For Further Credit to:
         Neotherapeutics, Inc.
         A/C # 561-04051-19-103

         The Company shall cause its transfer agent to transmit the Shares
electronically to the Purchaser by crediting the account set forth below through
the Deposit Withdrawal Agent Commission system.

Purchaser DWAC Instructions:

         --------------
         DTC #____
         --------------

<PAGE>

                                       2

                                    AGREED AND ACCEPTED:

                                    NeoTherapeutics, Inc.

                                    By:
                                       -----------------------------------------
                                       Name:
                                       Title:

                                    PURCHASER:

                                    [Purchaser Name]

                                    By:
                                       -----------------------------------------
                                       Name:
                                       Title:<PAGE>

                                                                   EXHIBIT 10.47

                             BRIGHTON CAPITAL, LTD.
                             1888 CENTURY PARK EAST
                                   SUITE 1900
                              LOS ANGELES, CA 90211
                       (310) 277-6095; FAX: (310) 277-6097

March 11, 2002
Mr. Sam Gulko, Chief Financial Officer
NeoTherapeutics, Inc.
157 Technology Drive
Irvine, CA  92618

Re: NeoTherapeutics, Inc.
    ---------------------

Dear Mr. Gulko:

This letter shall confirm the non-exclusive finder's arrangement between
Brighton Capital, Ltd. ("Brighton") and NeoTherapeutics, Inc. ("NEOT") in the
event that NEOT proceeds with a debt and/or equity transaction
("Transaction(s)") with a party introduced or procured by Brighton, even though
NEOT may have been previously introduced to that party by another. There is no
obligation to consummate any Transaction and NEOT can choose to accept or reject
any Transaction in its sole and absolute discretion. NEOT acknowledges that
there is no guaranty or assurance that any Transaction will take place and that
the final legal documentation may contain terms that vary with those set forth
on any term sheets. In the event that a Transaction(s) occurs, NEOT agrees to
pay Brighton the following at each close (or at Brighton's request, NEOT shall
direct the investor to pay the fees directly to Brighton) in cash (a) 6% (six)
of all cash amounts received and (b) 10,000 warrants per $1,000,000 funded. The
terms and conditions of the warrants including the exercise price and
registration rights shall be identical to those of the investor. NEOT agrees to
pay one-half of the fees each to Brighton and Atwood Capital, Ltd.

NEOT agrees to indemnify and hold harmless Brighton and its affiliates,
directors, officers, shareholders, employees and agents (the "Indemnified
Parties") against any and all losses, claims, damages or liabilities, joint or
several, including attorney's fees, to which the Indemnified Parties may become
subject, arising out of or related to actions taken or omitted to be taken by an
Indemnified Parties in connection with any service rendered, or any Transaction
or proposed Transaction contemplated, or any Indemnified Party's role in
connection therewith. In this regard, and without limitation, NEOT acknowledges
that Brighton is not responsible for the actions of the investor or its agents.
NEOT acknowledges that none of the Indemnified Parties is acting as attorney,
accountant, or financial advisor to NEOT and that NEOT will seek its own
professional advice with respect to the Transaction. Brighton and NEOT agree
that the obligations of each of the parties are solely corporate obligations,
and that no officer, director, employee, agent or shareholder of either party
shall be subjected to any personal liability whatsoever to any person, nor will
any claim for liability or suit be asserted by, or on behalf of, either Brighton
or NEOT. In the event of any dispute between the parties hereto, the parties

<PAGE>

Mr. Sam Gulko
March 11, 2002
Page 2 of 2

agree to resolve all matters in binding arbitration before the American
Arbitration Association in Los Angeles, CA with the prevailing party entitled to
reasonable attorney's fees and costs.

<PAGE>
Mr. Sam Gulko
March 11, 2002
Page 2 of 2

This agreement supercedes all other prior agreements between the parties named
herein.

NEOT agrees not to mention the name of Brighton or its agents in any press
release or new announcement without the written consent of Brighton.

Please acknowledge your agreement to the terms of this letter by executing a
copy of this letter where indicated below and returning it to us by fax at
310-277-6097. Please call me on my private line at 310-277-6092 if you have any
questions.

By: Brighton Capital, Ltd.               By: NeoTherapeutics, Inc.

     /s/Jeffrey Wolin                               /s/Sam Gulko
---------------------------              --------------------------------------
Jeffrey B. Wolin, President                Sam Gulko, Chief Financial Officer<PAGE>

                                                                   EXHIBIT 10.48

                          SECURITIES PURCHASE AGREEMENT

         This Securities Purchaser Agreement (the "Agreement") is made as of
March __, 2002 by and between _________________ ("Purchaser"), and
NeoTherapeutics, Inc. ("Company"), whereby the parties agree as follows:

         The Purchaser shall buy from the Company and the Company agrees to sell
to the Purchaser: (i) _______ shares (the "Shares") of the Company's common
stock, par value $.001 per share (the "Common Stock"), at a price of $2.00 per
share for an aggregate purchase price of $_________ (the "Purchase Price"), and
(ii) a five-year warrant to purchase up to __________ shares of Common Stock
(the "Warrant"), at an exercise price of $2.75 per share, in the form attached
hereto as Exhibit A.

         The Shares and the Warrant are being issued and sold pursuant to a
registration statement on Form S-3, File No. 333-53108, which registration
statement has been declared effective by the Securities and Exchange Commission.
The Company is delivering herewith a prospectus supplement on Form 424(b)(5)
regarding the issuance and sale of the Shares and the Warrant prior to funding,
a copy of which is attached hereto as Exhibit B. The Shares and Warrant are free
of restrictive legends and the Shares and the shares of Common Stock issuable
upon exercise of the Warrant, when issued upon exercise of the Warrant in
accordance with its terms and as described in the prospectus supplement, will be
free of any resale restrictions.

         Prior to the close of business on the date hereof:

         1.   The Purchaser shall wire the Purchase Price to the Company to the
              account set forth below.

                  Company Wire Transfer Instructions:

                  Chase Manhattan Bank
                  1 Chase Plaza
                  New York, NY 10004
                  ABA # 021 000 021
                  FBO Salomon Smith Barney
                  A/C # 066-198038
                  For Further Credit to:
                  Neotherapeutics, Inc.
                  A/C # 561-04051-19-103

         2.   The Company shall (A) deliver a facsimile copy of the Warrant to
              the Purchaser at the address for notices set forth below, with the
              original Warrant to be delivered to such address on the next
              following business day, and (B) cause its transfer agent to
              transmit the Shares electronically to the Purchaser by crediting
              the account set forth below through the Deposit Withdrawal Agent
              Commission system.

<PAGE>

                  Purchaser DWAC Instructions:

                  DTC No.:
                          ------------------------------------
                  Account No.:
                              --------------------------------
                  Reference:
                            ----------------------------------

         Notices to the Company shall be delivered to:

         NeoTherapeutics, Inc.
         Attention: Samuel Gulko
         Senior Vice President Finance, Chief Financial Officer, Secretary
         and Treasurer
         157 Technology Drive,
         Irvine, California  92618
         Facsimile:  (949) 788-6706

         Notices to Purchaser shall be delivered to:

         Purchaser Name:
                        --------------------------------------

         Attn:
                   -------------------------------------------

         Address:
                   -------------------------------------------

                   -------------------------------------------

         Facsimile:
                   -------------------------------------------

         Delivery of an executed copy of a signature page to this Agreement by
facsimile transmission shall be effective as delivery of a manually executed
copy of this Agreement and shall be effective and enforceable as the original.
This Agreement may be executed in one or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the
same instrument. This Agreement shall be governed and construed in accordance
with the internal laws of the State of California without giving effect to the
conflicts of law principles thereunder.

<PAGE>

AGREED AND ACCEPTED, as of the date indicated above:

NeoTherapeutics, Inc.

By:
      --------------------------------------------------
Name:
      --------------------------------------------------
Title:
      --------------------------------------------------

Purchaser Name:
               -----------------------------------------

By:
      --------------------------------------------------
Name:
      --------------------------------------------------
Title:
      --------------------------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}]]